Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA).


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 18 01 2021
accepted: 13 06 2021
entrez: 7 7 2021
pubmed: 8 7 2021
medline: 6 8 2021
Statut: epublish

Résumé

Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant disorder caused by pathogenic variants in either the TSC1 or TSC2 gene. Common manifestations of TSC have been grouped into major and minor clinical diagnostic criteria and assessed in clinical routine workup. However, case studies point towards the existence of rare disease manifestations and to the potential association of TSC with malignant tumors. In this study we sought to characterize rare manifestations and malignancies using a large cohort of patients. TuberOus SClerosis registry to increAse disease awareness (TOSCA) is a multicenter, international disease registry collecting clinical manifestations and characteristics of patients with TSC, both retrospectively and prospectively. We report rates and characteristics of rare manifestations and malignancies in patients with TSC who had enrolled in the TOSCA registry. We also examined these manifestations by age, sex, and genotype (TSC1 or TSC2). Overall, 2211 patients with TSC were enrolled in the study. Rare manifestations were reported in 382 (17.3%) study participants and malignancies in 65 (2.9%). Of these rare manifestations, the most frequent were bone sclerotic foci (39.5%), scoliosis (23%), thyroid adenoma (5.5%), adrenal angiomyolipoma (4.5%), hemihypertrophy and pancreatic neuroendocrine tumors (pNET; both 3.1%). These rare manifestations were more commonly observed in adults than children (66.2% vs. 22.7%), in females versus males (58.4% vs. 41.6%; except for scoliosis: 48.9% vs. 51.1%), and in those with TSC2 versus TSC1 (67.0% vs. 21.1%; except for thyroid adenoma: 42.9% vs. 57.1%). In the 65 individuals with reported malignancies, the most common were renal cell carcinoma (47.7%), followed by breast (10.8%) and thyroid cancer (9.2%). Although malignancies were more common in adult patients, 26.1% were reported in children and 63.1% in individuals < 40 years. TSC1 mutations were over-represented in individuals with malignancies compared to the overall TOSCA cohort (32.1% vs. 18.5%). Rare manifestations were observed in a significant proportion of individuals with TSC. We recommend further examination of rare manifestations in TSC. Collectively, malignancies were infrequent findings in our cohort. However, compared to the general population, malignant tumors occurred earlier in age and some tumor types were more common.

Sections du résumé

BACKGROUND
Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant disorder caused by pathogenic variants in either the TSC1 or TSC2 gene. Common manifestations of TSC have been grouped into major and minor clinical diagnostic criteria and assessed in clinical routine workup. However, case studies point towards the existence of rare disease manifestations and to the potential association of TSC with malignant tumors. In this study we sought to characterize rare manifestations and malignancies using a large cohort of patients.
METHODS
TuberOus SClerosis registry to increAse disease awareness (TOSCA) is a multicenter, international disease registry collecting clinical manifestations and characteristics of patients with TSC, both retrospectively and prospectively. We report rates and characteristics of rare manifestations and malignancies in patients with TSC who had enrolled in the TOSCA registry. We also examined these manifestations by age, sex, and genotype (TSC1 or TSC2).
RESULTS
Overall, 2211 patients with TSC were enrolled in the study. Rare manifestations were reported in 382 (17.3%) study participants and malignancies in 65 (2.9%). Of these rare manifestations, the most frequent were bone sclerotic foci (39.5%), scoliosis (23%), thyroid adenoma (5.5%), adrenal angiomyolipoma (4.5%), hemihypertrophy and pancreatic neuroendocrine tumors (pNET; both 3.1%). These rare manifestations were more commonly observed in adults than children (66.2% vs. 22.7%), in females versus males (58.4% vs. 41.6%; except for scoliosis: 48.9% vs. 51.1%), and in those with TSC2 versus TSC1 (67.0% vs. 21.1%; except for thyroid adenoma: 42.9% vs. 57.1%). In the 65 individuals with reported malignancies, the most common were renal cell carcinoma (47.7%), followed by breast (10.8%) and thyroid cancer (9.2%). Although malignancies were more common in adult patients, 26.1% were reported in children and 63.1% in individuals < 40 years. TSC1 mutations were over-represented in individuals with malignancies compared to the overall TOSCA cohort (32.1% vs. 18.5%).
CONCLUSION
Rare manifestations were observed in a significant proportion of individuals with TSC. We recommend further examination of rare manifestations in TSC. Collectively, malignancies were infrequent findings in our cohort. However, compared to the general population, malignant tumors occurred earlier in age and some tumor types were more common.

Identifiants

pubmed: 34229737
doi: 10.1186/s13023-021-01917-y
pii: 10.1186/s13023-021-01917-y
pmc: PMC8259106
doi:

Substances chimiques

Tuberous Sclerosis Complex 1 Protein 0
Tuberous Sclerosis Complex 2 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

301

Investigateurs

Nobuo Shinohara (N)
Shigeo Horie (S)
Masaya Kubota (M)
Jun Tohyama (J)
Katsumi Imai (K)
Mari Kaneda (M)
Hideo Kaneko (H)
Yasushi Uchida (Y)
Tomoko Kirino (T)
Shoichi Endo (S)
Yoshikazu Inoue (Y)
Katsuhisa Uruno (K)
Ayse Serdaroglu (A)
Zuhal Yapici (Z)
Banu Anlar (B)
Sakir Altunbasak (S)
Olga Lvova (O)
Oleg Valeryevich Belyaev (OV)
Oleg Agranovich (O)
Elena Vladislavovna Levitina (EV)
Yulia Vladimirovna Maksimova (YV)
Antonina Karas (A)
Yuwu Jiang (Y)
Liping Zou (L)
Kaifeng Xu (K)
Yushi Zhang (Y)
Guoming Luan (G)
Yuqin Zhang (Y)
Yi Wang (Y)
Meiling Jin (M)
Dingwei Ye (D)
Weiping Liao (W)
Liemin Zhou (L)
Jie Liu (J)
Jianxiang Liao (J)
Bo Yan (B)
Yanchun Deng (Y)
Li Jiang (L)
Zhisheng Liu (Z)
Shaoping Huang (S)
Hua Li (H)
Kijoong Kim (K)
Pei-Lung Chen (PL)
Hsiu-Fen Lee (HF)
Jeng-Dau Tsai (JD)
Ching-Shiang Chi (CS)
Chao-Ching Huang (CC)
Kate Riney (K)
Deborah Yates (D)
Patrick Kwan (P)
Surachai Likasitwattanakul (S)
Charcrin Nabangchang (C)
Lunliya Thampratankul Krisnachai Chomtho (LTK)
Kamornwan Katanyuwong (K)
Somjit Sriudomkajorn (S)
Jo Wilmshurst (J)
Reeval Segel (R)
Tal Gilboa (T)
Michal Tzadok (M)
Aviva Fattal- Valevski (AF)
Panagiotis Papathanasopoulos (P)
Antigone Syrigou Papavasiliou (AS)
Stylianos Giannakodimos (S)
Stylianos Gatzonis (S)
Evangelos Pavlou (E)
Meropi Tzoufi (M)
A M H Vergeer (AMH)
Marc Dhooghe (M)
Hélène Verhelst (H)
Filip Roelens (F)
Marie Cecile Nassogne (MC)
Pierre Defresne (P)
Liesbeth De Waele (L)
Patricia Leroy (P)
Nathalie Demonceau (N)
Benjamin Legros (B)
Patrick Van Bogaert (P)
Berten Ceulemans (B)
Lina Dom (L)
Pierre Castelnau (P)
Anne De Saint Martin (A)
Audrey Riquet (A)
Mathieu Milh (M)
Claude Cances (C)
Jean-Michel Pedespan (JM)
Dorothee Ville (D)
Agathe Roubertie (A)
Stéphane Auvin (S)
Patrick Berquin (P)
Christian Richelme (C)
Catherine Allaire (C)
Sophie Gueden (S)
Sylvie Nguyen The Tich (SNT)
Bertrand Godet (B)
Maria Luz Ruiz Falco Rojas (MLRF)
Jaume Campistol Planas (JC)
Antonio Martinez Bermejo (AM)
Patricia Smeyers Dura (PS)
Susana Roldan Aparicio (SR)
Maria Jesus Martinez Gonzalez (MJM)
Javier Lopez Pison (JL)
Manuel Oscar Blanco Barca (MOB)
Eduardo Lopez Laso (EL)
Olga Alonso Luengo (OA)
Francisco Javier Aguirre Rodriguez (FJA)
Ignacio Malaga Dieguez (IM)
Ana Camacho Salas (AC)
Itxaso Marti Carrera (IM)
Eduardo Martinez Salcedo (EM)
Maria Eugenia Yoldi Petri (MEY)
Ramon Cancho Candela (RC)
Ines da Conceicao Carrilho (I)
Jose Pedro Vieira (JP)
José Paulo da Silva Oliveira Monteiro (JP)
Miguel Jorge Santos de Oliveira Ferreira Leao (MJS)
Catarina Sofia Marceano Ribeiro Luis (CSMR)
Carla Pires Mendonca (CP)
Milda Endziniene (M)
Jurgis Strautmanis (J)
Inga Talvik (I)
Maria Paola Canevini (MP)
Antonio Gambardella (A)
Dario Pruna (D)
Salvatore Buono (S)
Elena Fontana (E)
Bernardo Dalla Bernardina (BD)
Carmen Burloiu (C)
Iuliu Stefan Bacos Cosma (ISB)
Mihaela Adela Vintan (MA)
Laura Popescu (L)
Karel Zitterbart (K)
Jaroslava Payerova (J)
Ladislav Bratsky (L)
Zuzana Zilinska (Z)
Ursula Gruber-Sedlmayr (U)
Matthias Baumann (M)
Edda Haberlandt (E)
Kevin Rostasy (K)
Ekaterina Pataraia (E)
Frances Elmslie (F)
Clare Ann Johnston (CA)
Pamela Crawford (P)
Peter Uldall (P)
Paul Uvebrant (P)
Olof Rask (O)
Marit Bjoernvold (M)
Eylert Brodtkorb (E)
Andreas Sloerdahl (A)
Ragnar Solhoff (R)
Martine Sofie Gilje Jaatun (MSG)
Marek Mandera (M)
Elzbieta Janina Radzikowska (EJ)
Mariusz Wysocki (M)
Michael Fischereder (M)
Gerhard Kurlemann (G)
Bernd Wilken (B)
Adelheid Wiemer-Kruel (A)
Klemens Budde (K)
Klaus Marquard (K)
Markus Knuf (M)
Andreas Hahn (A)
Hans Hartmann (H)
Andreas Merkenschlager (A)
Regina Trollmann (R)

Références

Orphanet J Rare Dis. 2017 Jan 5;12(1):2
pubmed: 28057044
Br J Radiol. 1988 Sep;61(729):851-3
pubmed: 3052686
Fam Cancer. 2018 Apr;17(2):275-280
pubmed: 28887784
Lancet. 2008 Aug 23;372(9639):657-68
pubmed: 18722871
Pediatrics. 1981 Feb;67(2):196-200
pubmed: 7243444
J Child Neurol. 2007 Jun;22(6):775-9
pubmed: 17641270
Orphanet J Rare Dis. 2014 Nov 26;9:182
pubmed: 25424195
J Med Genet. 1989 Jan;26(1):28-31
pubmed: 2918523
J Med Genet. 2013 Apr;50(4):255-63
pubmed: 23335809
J Child Neurol. 2014 Jul;29(7):912-9
pubmed: 24056157
Pediatr Neurol. 2013 Oct;49(4):243-54
pubmed: 24053982
Skeletal Radiol. 2015 Aug;44(8):1165-8
pubmed: 25616615
Australas Radiol. 1996 Feb;40(1):77-9
pubmed: 8838896
J Child Neurol. 1992 Apr;7(2):221-4
pubmed: 1573244
Am J Med Genet A. 2014 Jun;164A(6):1438-42
pubmed: 24668795
J Radiol. 1999 Apr;80(4):395-6
pubmed: 10337581
Dev Cell. 2015 Mar 9;32(5):617-30
pubmed: 25727005
Am J Med Genet A. 2016 Jun;170(6):1538-44
pubmed: 27061015
Am J Surg Pathol. 2014 Jul;38(7):895-909
pubmed: 24832166
Pediatr Nephrol. 2010 Aug;25(8):1555-61
pubmed: 20229188
Radiology. 2010 Mar;254(3):851-7
pubmed: 20177097
J Med Genet. 2011 Jul;48(7):444-9
pubmed: 21266383
Lancet. 1998 May 16;351(9114):1490
pubmed: 9605811
Pediatr Neurol. 2013 Oct;49(4):255-65
pubmed: 24053983
Pediatr Neurol. 2018 Jan;78:20-26
pubmed: 29249553

Auteurs

Matthias Sauter (M)

Klinikum Kempten, Klinikverbund Allgäu, Robert-Weixler-Str. 50, 87439, Kempten, Germany. Matthias.Sauter@klinikverbund-allgaeu.de.

Elena Belousova (E)

Research and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russian Federation.

Mirjana P Benedik (MP)

SPS Pediatrična Klinika, Ljubljana, Slovenia.

Tom Carter (T)

TSA Tuberous Sclerosis Association, Nottingham, UK.

Vincent Cottin (V)

Hôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, France.

Paolo Curatolo (P)

Tor Vergata University Hospital, Rome, Italy.

Maria Dahlin (M)

Karolinska University Hospital, Stockholm, Sweden.

Lisa D'Amato (L)

Novartis Farma S.P.A, Origgio, Italy.

Guillaume B d'Augères (GB)

Association Sclérose Tubéreuse de Bourneville, Gradignan, France.

Petrus J de Vries (PJ)

Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa.

José C Ferreira (JC)

Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.

Martha Feucht (M)

Universitätsklinik Für Kinder-Und Jugendheilkunde (Affiliated Partner of the ERN EpiCARE), Vienna, Austria.

Carla Fladrowski (C)

Associazione Sclerosi Tuberosa ONLUS, Milan, Italy.
In Den Birken, European Tuberous Sclerosis Complex Association, Dattein, Germany.

Christoph Hertzberg (C)

Vivantes-Klinikum Neukölln, Berlin, Germany.

Sergiusz Jozwiak (S)

Department of Child Neurology, Medical University of Warsaw, Warsaw, Poland.
Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland.

John A Lawson (JA)

The Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia.

Alfons Macaya (A)

Hospital Universitari Vall D'Hebron, Barcelona, Spain.

Ruben Marques (R)

Novartis Farma S.P.A, Origgio, Italy.
Institute of Biomedicine (IBIOMED), University of León, León, Spain.

Rima Nabbout (R)

Department of Pediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute, Paris Descartes University, Paris, France.

Finbar O'Callaghan (F)

Institute of Child Health, University College London, London, UK.

Jiong Qin (J)

Department of Pediatrics, Peking University People's Hospital, Beijing, China.

Valentin Sander (V)

Tallinn Children Hospital, Tallinn, Estonia.

Seema Shah (S)

Novartis Healthcare Pvt. Ltd, Hyderabad, India.

Yukitoshi Takahashi (Y)

National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Aoi-ku, UrushiyamaShizuoka, Japan.

Renaud Touraine (R)

Department of Genetics, CHU-Hôpital Nord, Saint Etienne, France.

Sotiris Youroukos (S)

St. Sophia Children's Hospital, Athens, Greece.

Bernard Zonnenberg (B)

University Medical Center, Utrecht, The Netherlands.

Anna Jansen (A)

Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel VUB, Brussels, Belgium.

J Chris Kingswood (JC)

Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH